Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Research analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for Amgen in a research note issued to ...

Investment analysts at William Blair reduced their FY2025 earnings per share estimates for Amgen in a report released on Wednesday, February 5th. William Blair analyst M. Phipps now anticipates that ...

What Happened: Grygiel's recent move involves selling 1,589 shares of Amgen. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Friday. The total ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

But this week, the stock jumped again after Amgen issued a strong financial update Tuesday. Its rise helped push up the S&P ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

AMGN beats fourth-quarter estimates for earnings and sales. FDA places clinical hold on a phase I study on its obesity ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...